Psoriasis Therapeutics Market Trends, Size, Top Players 2031
The Psoriasis Therapeutics Market is expected to register a CAGR of 8.4% from 2024 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Drug Class ( TNF Inhibitors, PDE4 Inhibitors, Interleukin Blockers, Others ). The report further presents analysis based on the Molecule Type ( Biologics, Small Molecules ). The report is segmented by Route of Administration ( Oral, Parenteral, Topical ). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Psoriasis Therapeutics Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Psoriasis Therapeutics Market Segmentation
Drug Class- TNF Inhibitors
- PDE4 Inhibitors
- Interleukin Blockers
- Others
- Biologics
- Small Molecules
- Oral
- Parenteral
- Topical
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Strategic Insights
Psoriasis Therapeutics Market Growth Drivers- Growing Number of Patients with Psoriasis: People suffering from psoriasis worldwide number about 2-3% of the total population and increase, especially in countries like North America and Europe, where psoriasis traumas millions. In the face of the ever-increasing population age, it is even estimated that the incidence of psoriasis will be greater than that within the current population. With such a burgeoning patient base, there grows increased demand for effective treatments and corresponding markets in therapeutics for psoriasis. Growing awareness regarding the condition registered and indeed improving diagnostic methods adds to the burden of diagnosed cases and thus increases the market dimensions.
- Get Updated Breakthroughs through Biological plus Targeted Therapies: The innovations of biologics and newer classes of targeted therapy have indeed redefined the treatment courses for psoriatics. Among the biologics are TNF-alpha inhibitors, IL-12/23 inhibitors, and IL-17 inhibitors, all of which have shown an extremely effective result in the management of moderate-to-severe psoriasis. These new agents directly and collectively act on those immune system pathways that mediate the inflammatory process, providing relief henceforth and minimizing adverse effects when compared with systemic steroids.
- Awareness & Diagnosis Rising: Patient and provider awareness of psoriasis has changed the future for treating the disease. Educational and awareness campaigns are encouraging many more people to ask questions and be diagnosed by physicians. Early recognition leads to speedy, appropriate strategies for effective treatment, which furthers patients' quality of living, plus benefits from advances in molecular diagnostics, genotype, and biomarker development. Thus, more personalized and accurate approaches are also driving the uptake of therapeutic solutions for psoriasis.
- Customized Treatment Approach: In the context of this shift, the emerging market for psoriasis therapeutics will be focused more on personalized medicine. The person's particular needs become the parameter around which the treatment is planned. The parameters on which personalized treatment plans are based include disease severity, genetic markers, and the responses to previous therapies. New advances in genomics and biomarker identification allow healthcare providers to select the most appropriate therapy for each patient, increasing the chance of successful outcomes.
- The Demand Emergence of Oral Therapies Pipeline: Biologics have dominated the treatment of psoriasis in the past few years, but oral therapeutics have made inroads through convenience and simplicity compared with injection. JAK inhibitors, phosphodiesterase inhibitors, and other new small-molecule candidates are being explored in clinical trials. These would probably provide much of the patient population with much easier alternatives to treatment, freeing them from injections or visits to hospitals and, hence, improving compliance. These drugs will not stand alone but will rather supplement existing treatments and provide options for future management of psoriasis.
- Introduction of Combined Therapies: New therapeutic modalities are emerging in combination therapy for the treatment of psoriasis. Biologics combined with conventional topical agents or other systemic agents provide new treatment possibilities to allow much better control over the disease. This is particularly important in cases of severe psoriasis, as well as in patients who do not respond to the previous monotherapy. Another area of emphasis will be the development of combination therapies targeting the different pathways of the disease mechanism.
- Advancement of Innovative Biologicals and Biosimilars: There is a window of opportunity that is being opened for the biosimilars market in the psoriasis therapeutics as many blockbuster biologics are losing patent protections. Biosimilars make biologics affordable so many more patients can benefit from them. Entry of these products into established as well as new markets will create an access point for companies to enter into the lucrative market of psoriasis treatments offering consumers economical options between those that branded biologics have not made accessible otherwise.
- Increased Concentrations on Early Interventions: As healthcare systems adopt early diagnosis and treatment of chronic diseases, there is an increasing scope to develop therapies initiated at early stages of psoriasis. Intervention early in the disease may prevent escalation and improve long-term health outcomes. The pillar under development is for novel drugs for mild-to-moderate psoriasis, which can be used early in the disease course, since pharmaceutical companies see this as forming an entire new market for innovative therapies.
- Blending with Digital Health Technologies: An area that is emerging as a huge opportunity for improving psoriasis management is the blending of digital health technologies such as mobile apps and telemedicine. They enable one to be able to view and document how the disease has progressed and how the treatment has improved. Increasingly popular are mobile applications with their features of tracking skin condition, medication adherence, and overall general health in psoriasis patients. Technologies put in place by investment complemented by market solutions readily place companies ahead in the competition.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Psoriasis Therapeutics Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Psoriasis Therapeutics Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Psoriasis Therapeutics Market is estimated to witness a CAGR of 8.4% from 2023 to 2031
The major factors driving the Psoriasis Therapeutics market are:
1. Increasing Prevalence of Psoriasis
2. Advancements in Biologic and Targeted Therapies
Development of Novel Biologics and Biosimilars act as a opportunity for growth of the market in forecast period.
North America region dominated the Psoriasis Therapeutics market in 2023.
Biiologics segment, by molecule type, dominated the market in 2023.
Players operating in the market are Astellas Pharma Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, GlaxoSmithKline plc, Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., Biocon Limited, Eli Lilly and Company, G & W Laboratories Inc.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Psoriasis Therapeutics Market - By Drug Class
1.3.2 Psoriasis Therapeutics Market - By Molecule Type
1.3.3 Psoriasis Therapeutics Market - By Route of Administration
1.3.4 Psoriasis Therapeutics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PSORIASIS THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PSORIASIS THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PSORIASIS THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. PSORIASIS THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. PSORIASIS THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. PSORIASIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. TNF INHIBITORS
7.3.1. Overview
7.3.2. TNF Inhibitors Market Forecast and Analysis
7.4. PDE4 INHIBITORS
7.4.1. Overview
7.4.2. PDE4 Inhibitors Market Forecast and Analysis
7.5. INTERLEUKIN BLOCKERS
7.5.1. Overview
7.5.2. Interleukin Blockers Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. PSORIASIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - MOLECULE TYPE
8.1. OVERVIEW
8.2. MOLECULE TYPE MARKET FORECASTS AND ANALYSIS
8.3. BIOLOGICS
8.3.1. Overview
8.3.2. Biologics Market Forecast and Analysis
8.4. SMALL MOLECULES
8.4.1. Overview
8.4.2. Small Molecules Market Forecast and Analysis
9. PSORIASIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. ORAL
9.3.1. Overview
9.3.2. Oral Market Forecast and Analysis
9.4. PARENTERAL
9.4.1. Overview
9.4.2. Parenteral Market Forecast and Analysis
9.5. TOPICAL
9.5.1. Overview
9.5.2. Topical Market Forecast and Analysis
10. PSORIASIS THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Psoriasis Therapeutics Market Overview
10.1.2 North America Psoriasis Therapeutics Market Forecasts and Analysis
10.1.3 North America Psoriasis Therapeutics Market Forecasts and Analysis - By Drug Class
10.1.4 North America Psoriasis Therapeutics Market Forecasts and Analysis - By Molecule Type
10.1.5 North America Psoriasis Therapeutics Market Forecasts and Analysis - By Route of Administration
10.1.6 North America Psoriasis Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Psoriasis Therapeutics Market
10.1.6.1.1 United States Psoriasis Therapeutics Market by Drug Class
10.1.6.1.2 United States Psoriasis Therapeutics Market by Molecule Type
10.1.6.1.3 United States Psoriasis Therapeutics Market by Route of Administration
10.1.6.2 Canada Psoriasis Therapeutics Market
10.1.6.2.1 Canada Psoriasis Therapeutics Market by Drug Class
10.1.6.2.2 Canada Psoriasis Therapeutics Market by Molecule Type
10.1.6.2.3 Canada Psoriasis Therapeutics Market by Route of Administration
10.1.6.3 Mexico Psoriasis Therapeutics Market
10.1.6.3.1 Mexico Psoriasis Therapeutics Market by Drug Class
10.1.6.3.2 Mexico Psoriasis Therapeutics Market by Molecule Type
10.1.6.3.3 Mexico Psoriasis Therapeutics Market by Route of Administration
10.2. EUROPE
10.2.1 Europe Psoriasis Therapeutics Market Overview
10.2.2 Europe Psoriasis Therapeutics Market Forecasts and Analysis
10.2.3 Europe Psoriasis Therapeutics Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Psoriasis Therapeutics Market Forecasts and Analysis - By Molecule Type
10.2.5 Europe Psoriasis Therapeutics Market Forecasts and Analysis - By Route of Administration
10.2.6 Europe Psoriasis Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Psoriasis Therapeutics Market
10.2.6.1.1 Germany Psoriasis Therapeutics Market by Drug Class
10.2.6.1.2 Germany Psoriasis Therapeutics Market by Molecule Type
10.2.6.1.3 Germany Psoriasis Therapeutics Market by Route of Administration
10.2.6.2 France Psoriasis Therapeutics Market
10.2.6.2.1 France Psoriasis Therapeutics Market by Drug Class
10.2.6.2.2 France Psoriasis Therapeutics Market by Molecule Type
10.2.6.2.3 France Psoriasis Therapeutics Market by Route of Administration
10.2.6.3 Italy Psoriasis Therapeutics Market
10.2.6.3.1 Italy Psoriasis Therapeutics Market by Drug Class
10.2.6.3.2 Italy Psoriasis Therapeutics Market by Molecule Type
10.2.6.3.3 Italy Psoriasis Therapeutics Market by Route of Administration
10.2.6.4 Spain Psoriasis Therapeutics Market
10.2.6.4.1 Spain Psoriasis Therapeutics Market by Drug Class
10.2.6.4.2 Spain Psoriasis Therapeutics Market by Molecule Type
10.2.6.4.3 Spain Psoriasis Therapeutics Market by Route of Administration
10.2.6.5 United Kingdom Psoriasis Therapeutics Market
10.2.6.5.1 United Kingdom Psoriasis Therapeutics Market by Drug Class
10.2.6.5.2 United Kingdom Psoriasis Therapeutics Market by Molecule Type
10.2.6.5.3 United Kingdom Psoriasis Therapeutics Market by Route of Administration
10.2.6.6 Rest of Europe Psoriasis Therapeutics Market
10.2.6.6.1 Rest of Europe Psoriasis Therapeutics Market by Drug Class
10.2.6.6.2 Rest of Europe Psoriasis Therapeutics Market by Molecule Type
10.2.6.6.3 Rest of Europe Psoriasis Therapeutics Market by Route of Administration
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Psoriasis Therapeutics Market Overview
10.3.2 Asia-Pacific Psoriasis Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Psoriasis Therapeutics Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Psoriasis Therapeutics Market Forecasts and Analysis - By Molecule Type
10.3.5 Asia-Pacific Psoriasis Therapeutics Market Forecasts and Analysis - By Route of Administration
10.3.6 Asia-Pacific Psoriasis Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Psoriasis Therapeutics Market
10.3.6.1.1 Australia Psoriasis Therapeutics Market by Drug Class
10.3.6.1.2 Australia Psoriasis Therapeutics Market by Molecule Type
10.3.6.1.3 Australia Psoriasis Therapeutics Market by Route of Administration
10.3.6.2 China Psoriasis Therapeutics Market
10.3.6.2.1 China Psoriasis Therapeutics Market by Drug Class
10.3.6.2.2 China Psoriasis Therapeutics Market by Molecule Type
10.3.6.2.3 China Psoriasis Therapeutics Market by Route of Administration
10.3.6.3 India Psoriasis Therapeutics Market
10.3.6.3.1 India Psoriasis Therapeutics Market by Drug Class
10.3.6.3.2 India Psoriasis Therapeutics Market by Molecule Type
10.3.6.3.3 India Psoriasis Therapeutics Market by Route of Administration
10.3.6.4 Japan Psoriasis Therapeutics Market
10.3.6.4.1 Japan Psoriasis Therapeutics Market by Drug Class
10.3.6.4.2 Japan Psoriasis Therapeutics Market by Molecule Type
10.3.6.4.3 Japan Psoriasis Therapeutics Market by Route of Administration
10.3.6.5 South Korea Psoriasis Therapeutics Market
10.3.6.5.1 South Korea Psoriasis Therapeutics Market by Drug Class
10.3.6.5.2 South Korea Psoriasis Therapeutics Market by Molecule Type
10.3.6.5.3 South Korea Psoriasis Therapeutics Market by Route of Administration
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Psoriasis Therapeutics Market Overview
10.4.2 Middle East and Africa Psoriasis Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Psoriasis Therapeutics Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Psoriasis Therapeutics Market Forecasts and Analysis - By Molecule Type
10.4.5 Middle East and Africa Psoriasis Therapeutics Market Forecasts and Analysis - By Route of Administration
10.4.6 Middle East and Africa Psoriasis Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Psoriasis Therapeutics Market
10.4.6.1.1 South Africa Psoriasis Therapeutics Market by Drug Class
10.4.6.1.2 South Africa Psoriasis Therapeutics Market by Molecule Type
10.4.6.1.3 South Africa Psoriasis Therapeutics Market by Route of Administration
10.4.6.2 Saudi Arabia Psoriasis Therapeutics Market
10.4.6.2.1 Saudi Arabia Psoriasis Therapeutics Market by Drug Class
10.4.6.2.2 Saudi Arabia Psoriasis Therapeutics Market by Molecule Type
10.4.6.2.3 Saudi Arabia Psoriasis Therapeutics Market by Route of Administration
10.4.6.3 U.A.E Psoriasis Therapeutics Market
10.4.6.3.1 U.A.E Psoriasis Therapeutics Market by Drug Class
10.4.6.3.2 U.A.E Psoriasis Therapeutics Market by Molecule Type
10.4.6.3.3 U.A.E Psoriasis Therapeutics Market by Route of Administration
10.4.6.4 Rest of Middle East and Africa Psoriasis Therapeutics Market
10.4.6.4.1 Rest of Middle East and Africa Psoriasis Therapeutics Market by Drug Class
10.4.6.4.2 Rest of Middle East and Africa Psoriasis Therapeutics Market by Molecule Type
10.4.6.4.3 Rest of Middle East and Africa Psoriasis Therapeutics Market by Route of Administration
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Psoriasis Therapeutics Market Overview
10.5.2 South and Central America Psoriasis Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Psoriasis Therapeutics Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Psoriasis Therapeutics Market Forecasts and Analysis - By Molecule Type
10.5.5 South and Central America Psoriasis Therapeutics Market Forecasts and Analysis - By Route of Administration
10.5.6 South and Central America Psoriasis Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Psoriasis Therapeutics Market
10.5.6.1.1 Brazil Psoriasis Therapeutics Market by Drug Class
10.5.6.1.2 Brazil Psoriasis Therapeutics Market by Molecule Type
10.5.6.1.3 Brazil Psoriasis Therapeutics Market by Route of Administration
10.5.6.2 Argentina Psoriasis Therapeutics Market
10.5.6.2.1 Argentina Psoriasis Therapeutics Market by Drug Class
10.5.6.2.2 Argentina Psoriasis Therapeutics Market by Molecule Type
10.5.6.2.3 Argentina Psoriasis Therapeutics Market by Route of Administration
10.5.6.3 Rest of South and Central America Psoriasis Therapeutics Market
10.5.6.3.1 Rest of South and Central America Psoriasis Therapeutics Market by Drug Class
10.5.6.3.2 Rest of South and Central America Psoriasis Therapeutics Market by Molecule Type
10.5.6.3.3 Rest of South and Central America Psoriasis Therapeutics Market by Route of Administration
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL PSORIASIS THERAPEUTICS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. PSORIASIS THERAPEUTICS MARKET, KEY COMPANY PROFILES
13.1. ASTELLAS PHARMA INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. ASTRAZENECA PLC,
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. BOEHRINGER INGELHEIM GMBH
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. F. HOFFFMANN-LA ROCHE
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. GLAXOSMITHKLINE PLC
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. MERCK AND CO., INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. BIOCON LIMITED
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. ELI LILLY AND COMPANY
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. G AND W LABORATORIES INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies
1. Astellas Pharma Inc.
2. AstraZeneca plc,
3. Boehringer Ingelheim GmbH
4. F. Hofffmann-La Roche
5. GlaxoSmithKline plc
6. Merck & Co., Inc.
7. Valeant Pharmaceuticals International, Inc.
8. Biocon Limited
9. Eli Lilly and Company
10. G & W Laboratories Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For